These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 210669)

  • 1. Effect of immunization on the development of latent ganglionic infection in mice challenged intravaginally with herpes simplex virus types 1 and 2.
    Asher LV; Walz MA; Notkins AL
    Am J Obstet Gynecol; 1978 Aug; 131(7):788-91. PubMed ID: 210669
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Latent infection of sensory ganglia with herpes simplex virus: efficacy of immunization.
    Price RW; Walz MA; Wohlenberg C; Notkins AL
    Science; 1975 May; 188(4191):938-40. PubMed ID: 166432
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune responses in mice against herpes simplex virus: mechanisms of protection against facial and ganglionic infections.
    Zweerink HJ; Martinez D; Lynch RJ; Stanton LW
    Infect Immun; 1981 Jan; 31(1):267-75. PubMed ID: 6260662
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunization with a vaccinia virus recombinant expressing herpes simplex virus type 1 glycoprotein D: long-term protection and effect of revaccination.
    Rooney JF; Wohlenberg C; Cremer KJ; Moss B; Notkins AL
    J Virol; 1988 May; 62(5):1530-4. PubMed ID: 2833606
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunization of experimental animals with reconstituted glycoprotein mixtures of herpes simplex virus 1 and 2: protection against challenge with virulent virus.
    Meignier B; Jourdier TM; Norrild B; Pereira L; Roizman B
    J Infect Dis; 1987 May; 155(5):921-30. PubMed ID: 3031174
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute and latent herpes simplex virus neurological disease in mice immunized with purified virus-specific glycoproteins gB or gD.
    Dix RD; Mills J
    J Med Virol; 1985 Sep; 17(1):9-18. PubMed ID: 2995573
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of immunization on acute and latent infections of vaginouterine tissue with herpes simplex virus types 1 and 2.
    Walz MA; Price RW; Hayashi K; Katz BJ; Notkins AL
    J Infect Dis; 1977 May; 135(5):744-52. PubMed ID: 192810
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Host defenses in herpes simplex infections of the nervous system: effect of antibody on disease and viral spread.
    McKendall RR; Klassen T; Baringer JR
    Infect Immun; 1979 Feb; 23(2):305-11. PubMed ID: 217828
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mucosal and systemic antiviral antibodies in mice inoculated intravaginally with herpes simplex virus type 2.
    McDermott MR; Brais LJ; Evelegh MJ
    J Gen Virol; 1990 Jul; 71 ( Pt 7)():1497-504. PubMed ID: 2165134
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccinia virus recombinant expressing herpes simplex virus type 1 glycoprotein D prevents latent herpes in mice.
    Cremer KJ; Mackett M; Wohlenberg C; Notkins AL; Moss B
    Science; 1985 May; 228(4700):737-40. PubMed ID: 2986288
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Herpes simplex virus type 1 infection in mice with severe combined immunodeficiency (SCID).
    Minagawa H; Sakuma S; Mohri S; Mori R; Watanabe T
    Arch Virol; 1988; 103(1-2):73-82. PubMed ID: 2850780
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Contributions of antibody and T cell subsets to protection elicited by immunization with a replication-defective mutant of herpes simplex virus type 1.
    Morrison LA; Knipe DM
    Virology; 1997 Dec; 239(2):315-26. PubMed ID: 9434723
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Latency of herpes simplex virus in absence of neutralizing antibody: model for reactivation.
    Sekizawa T; Openshaw H; Wohlenberg C; Notkins AL
    Science; 1980 Nov; 210(4473):1026-8. PubMed ID: 6254149
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of monoclonal antibody directed against herpes simplex virus glycoproteins to protect mice against acute virus-induced neurological disease.
    Dix RD; Pereira L; Baringer JR
    Infect Immun; 1981 Oct; 34(1):192-9. PubMed ID: 6271681
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of a virion envelope herpes simplex virus vaccine against experimental skin infections in hairless mice.
    Klein RJ; Buimovici-Klein E; Moser H; Moucha R; Hilfenhaus J
    Arch Virol; 1981; 68(2):73-80. PubMed ID: 6264897
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity of herpes simplex virus type 1 glycoproteins expressed in vaccinia virus recombinants.
    Blacklaws BA; Krishna S; Minson AC; Nash AA
    Virology; 1990 Aug; 177(2):727-36. PubMed ID: 2164732
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of herpes simplex virus type 1 immunization in protecting against acute and latent infection by herpes simplex virus type 2 in mice.
    McKendall RR
    Infect Immun; 1977 May; 16(2):717-9. PubMed ID: 193798
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Different mechanisms of protection by monoclonal and polyclonal antibodies during the course of herpes simplex virus infection.
    Eis-Hübinger AM; Mohr K; Schneweis KE
    Intervirology; 1991; 32(6):351-60. PubMed ID: 1657825
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protection of guinea pigs from primary and recurrent herpes simplex virus (HSV) type 2 cutaneous disease with vaccinia virus recombinants expressing HSV glycoprotein D.
    Wachsman M; Aurelian L; Smith CC; Lipinskas BR; Perkus ME; Paoletti E
    J Infect Dis; 1987 Jun; 155(6):1188-97. PubMed ID: 3033094
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunized mice challenged with herpes simplex virus by the intranasal route show protection against latent infection.
    Rooney JF; Wohlenberg C; Cremer KJ; Notkins AL
    J Infect Dis; 1989 May; 159(5):974-6. PubMed ID: 2540251
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.